文献速递艾滋病与性传播感染

初治HIV感染者启动多替拉韦方案体重增加更显著

Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该队列研究纳入1152例初治HIV成人,比较INSTI、PI和NNRTI方案启动后的体重变化。18个月时多替拉韦组体重增加6.0 kg,显著高于NNRTI组2.6 kg和艾维雷韦组0.5 kg(均P<.05),但与拉替拉韦和PI组的差异无统计学意义。

要点

  • 初治启动多替拉韦方案18个月体重增加6.0 kg,高于NNRTI的2.6 kg和艾维雷韦的0.5 kg。
  • 多替拉韦与拉替拉韦(3.4 kg)及PI(4.1 kg)的体重差异无统计学意义。
  • 各ART类别18个月病毒学抑制率相似。

核心结论

  • 初治HIV感染者启动含多替拉韦方案18个月体重增加显著高于含NNRTI或艾维雷韦方案。

研究设计与样本

  • 范德堡综合护理门诊队列中2007年1月至2016年6月启动INSTI、PI或NNRTI方案的成人初治HIV感染者,共1152例。
  • 采用多变量线性混合效应模型预测体重,限制性立方样条放松线性假设,自举法生成95%置信区间。

主要发现

  • 1152例中351例启动INSTI方案(多替拉韦135例、艾维雷韦153例、拉替拉韦63例),86%为男性,49%为白人。
  • 启动ART时中位年龄35岁,BMI 25.1 kg/m2,CD4+ T细胞计数318 cells/μL。
  • 18个月时多替拉韦组体重增加6.0 kg,NNRTI组2.6 kg(P < .05),艾维雷韦组0.5 kg(P < .05)。
  • 18个月时多替拉韦组体重增加高于拉替拉韦组3.4 kg和PI组4.1 kg,但差异无统计学意义。
  • 不同ART类别18个月病毒学抑制率相似。

临床怎么用

  • 初治HIV感染者选择多替拉韦方案时应关注体重变化,尤其与NNRTI或艾维雷韦方案比较时。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent studies have reported weight gain in virologically suppressed persons living with human immunodeficiency virus (PLWH) switched from older antiretroviral therapy (ART) to newer integrase strand transfer inhibitor (INSTI)-based regimens. In this study, we investigated whether weight gain differs among treatment-naive PLWH starting INSTI-based regimens compared to other ART regimens. METHODS: Adult, treatment-naive PLWH in the Vanderbilt Comprehensive Care Clinic cohort initiating INSTI-, protease inhibitor (PI)-, and nonnucleoside reverse transcriptase inhibitor (NNRTI)-based ART between January 2007 and June 2016 were included. We used multivariable linear mixed-effects models to generate marginal predictions of weights over time, adjusting for baseline clinical and demographic characteristics. We used restricted cubic splines to relax linearity assumptions and bootstrapping to generate 95% confidence intervals. RESULTS: Among 1152 ART-naive PLWH, 351 initiated INSTI-based regimens (135 dolutegravir, 153 elvitegravir, and 63 raltegravir), 86% were male, and 49% were white. At ART initiation, median age was 35 years, body mass index was 25.1 kg/m2, and CD4+ T-cell count was 318 cells/μL. Virologic suppression at 18 months was similar between different ART classes. At all examined study time points, weight gain was highest among PLWH starting dolutegravir. At 18 months, PLWH on dolutegravir gained 6.0 kg, compared to 2.6 kg for NNRTIs (P < .05), and 0.5 kg for elvitegravir (P < .05). PLWH starting dolutegravir also gained more weight at 18 months compared to raltegravir (3.4 kg) and PIs (4.1 kg), though these differences were not statistically significant. CONCLUSIONS: Treatment-naive PLWH starting dolutegravir-based regimens gained significantly more weight at 18 months than those starting NNRTI-based and elvitegravir-based regimens.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Bourgi K, Rebeiro PF, Turner M, et al. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy. Clin Infect Dis. 2020. PMID: 31100116. doi:10.1093/cid/ciz407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。